Anabaseine 

Anabaseine is a non-selective nicotinic agonist. Anabaseine stimulates all AChRs, preferentially stimulates skeletal muscle and brain α7 subtypes^[1][2]. Anabaseine is also a weak partial agonist at α4β2 nAChRs^[3].

AChRs^[1]

Anabaseine is a full agonist at α7 AChR in the central nervous system (CNS) and a full agonist at α1β1ɛδ and α1β1γδ (Torpedo) in the peripheral nervous system^[1].
Anabaseine acts as neuromuscular agonist on the frog rectus abdominis muscle (EC₅₀: 0.25-0.74 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anabaseine (3.6 μmol/kg; subcutaneous injection) elevates ACh levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

160.22

C₁₀H₁₂N₂

3471-05-4

Oil

Light brown to brown

C1(C2=CC=CN=C2)=NCCCC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kem W, et al. The Nemertine Toxin Anabaseine and Its Derivative DMXBA (GTS-21): Chemical and Pharmacological Properties. Mar Drugs. 2006;4(3):255-273.

  [2]. Summers KL et al. Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn J Pharmacol. 1997 Jun;74(2):139-46.  [Content Brief]

  [3]. Andrud K, et al. Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine. Mar Drugs. 2019;17(11):614. Published 2019 Oct 29.  [Content Brief]